spacer
home > pmps > summer 2017 > see attached
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

See Attached

PMPS: What are the most innovative and effective delivery systems currently available in parenteral technologies and why?

Dr Mike Schaefers: In the current market, combination products are becoming more popular, and one of the most innovative types is wearable drug delivery systems. For most patients with chronic conditions who must regularly self-inject doses of medication, an easy-to-use, integrated delivery and administration system such as a wearable injector can be key to creating the reliability that allows for compliance with treatment plans.

For example, a single-use, electronic wearable injector that adheres to the patientís body is discreet, intuitive and designed to minimise discomfort. These can be pre-programmed to deliver high volumes of viscous or sensitive products over time, making self-administration of medication easier for the patient outside of the clinical setting.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Mike Schaefers, Vice President (VP) of Global Product Management and Marketing Operations at West Pharmaceutical Services, Inc., is responsible for building and executing the enterprise-wide product portfolio strategy. He previously served as VP in Global Marketing for the companyís Packaging System Division. He joined West in 2000 as Director of the Technical Customer Service Group for the European and Asia- Pacific markets, before becoming VP of Marketing in Europe, responsible for the regionís marketing and technical support. Dr Schaefers earned his PhD in chemistry from Ruhr University in Bochum, Germany, and a diploma in business management from IHK in Essen, Germany.
spacer
Dr Mike Schaefers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Acquires KWS BioTest

WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 11, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS enhances Charles Riverís discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.
More info >>

White Papers

Clinical Research in Spain

BioClever

This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>

 
Industry Events

PHARM Connect Congress 2018

13-14 March 2018, Corinthia Hotel Budapest, Hungary

PHARM Connect Congress is the premier networking business event dedicated to pharmaceutical and biotechnology innovations and trends from development through commercialization in Central and Eastern Europe and the CIS region. The two days event offers the perfect setting for solution providers to present their products and services directly to key decision makers playing a key role in the pharmaceutical industry in Central Eastern Europe.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement